Poly-beta-amino-ester licofelone conjugates development for osteoarthritis treatment.

ABSTRACT: Disease-modifying osteoarthritis drugs (DMOADs) are a new therapeutic class for osteoarthritis (OA) prevention or inhibition of the disease development. Unfortunately, none of the DMOADs have been clinically approved due to their poor therapeutic performances in clinical trials. The joint environment has played a role in this process by limiting the amount of drug effectively delivered as well as the time that the drug stays within the joint space. The current study aimed to improve the delivery of the DMOADs into cartilage tissue by increasing uptake and retention time of the DMOADs within the tissue. Licofelone was used a model DMOAD due to its significant therapeutic effect against OA progression as shown in the recent phase III clinical trial. For this purpose licofelone was covalently

SUBMITTER: Alghamdi R 

PROVIDER: S-EPMC10758810 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature